# US 2012/0252775 A1 · Method for diagnosing, preventing, and treating neurological diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252775 A1
- Document ID: US20120252775A1
- Status: Published application
- Kind: A1
- Application number: 13/117,073
- Filed: 2011-05-26
- Published: 2012-10-04
- Earliest claimed: 2010-05-26
- Assignees: The United States of America as represented by the Department of Veterans Affairs
- Inventors: Sydney Martin Finegold
- Web page: https://patentgrep.com/patent/US20120252775A1

## CPC

- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/397: having four-membered rings, e.g. azetidine
- A61K 31/424: condensed with heterocyclic ring systems, e.g. clavulanic acid
- A61K 31/43: Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula [IMAGE cpc-sch-A61K-0952.gif], e.g. penicillins, penems
- A61K 31/431: containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61K 35/745: Bifidobacteria
- A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C12Q 1/18: Testing for antimicrobial activity of a material
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention provides for methods of treating autism associated with Desulfovibrio overgrowth in the gastrointestinal tract of a patient, said method comprising administering to the patient suffering from said autism a treatment course of aztreonam in an amount effective to treat autism in the patient, thereby treating autism.

## Claims

### Claim 1

A method of treating autism associated with Desulfovibrio overgrowth in the gastrointestinal tract of a patient, said method comprising administering to the patient suffering from said autism a treatment course of aztreonam in an amount effective to treat autism in the patient, thereby treating autism.

### Claim 2 (depends on 1)

The method claim 1, further comprising administering a beta-lactamase inhibitor.

### Claim 3 (depends on 2)

The method of claim 2, wherein the beta-lactamase inhibitor is selected from the group consisting of clavulanic acid, tazobactam, sulbactam and LK-157 or others.

### Claim 4 (depends on 1)

The method of claim 1, wherein aztreonam and the beta-lactamase inhibitor are administered concurrently.

### Claim 5

A method for screening for compounds that inhibit Desulfovibrio and thereby inhibit autism, wherein said method comprises:
a) obtaining a sample from a subject,
a) contacting a sample containing Desulfovibrio with a molecule of interest,
b) determining whether contact results in inhibition of Desulfovibrio.

### Claim 6 (depends on 5)

The method of claim 5, wherein the compound is bacteriostatic.

### Claim 7 (depends on 5)

The method of claim 5, wherein the compound is bactericidal.

### Claim 8 (depends on 5)

The method of claim 5, wherein the compound is a small molecule, protein, peptide, antibiotic, pre-formed antibodies, bacteriophage or a combination thereof.

### Claim 9 (depends on 5)

A screening method according to claim 5, which comprises separately contacting each of a plurality of samples to be tested.

### Claim 10 (depends on 9)

The screening method of claim 9, wherein the plurality of samples comprises more than about 104 samples.

### Claim 11 (depends on 9)

The screening method of claim 9, wherein the plurality of samples comprises more than about 5×104 samples.

### Claim 12 (depends on 5)

The method of claim 5, wherein the subject is selected from the group consisting of human, monkey, ape, dog, cat, cow, horse, rabbit, mouse and rat subjects.

### Claim 13

A method of screening for autism comprising:
a) obtaining a sample from a subject, and
b) determining whether Desulfovibrio is present in the sample, the presence of Desulfovibrio being indicative of autism.

### Claim 14 (depends on 13)

The method of claim 13, wherein the subject is human.

### Claim 15 (depends on 5)

The method of claim 5, wherein the sample is selected from the group consisting of feces, urine, blood and plasma.

### Claim 16 (depends on 5)

The method of claim 5, wherein inhibition of Desulfovibrio comprises decrease in growth of Desulfovibrio, elimination of growth of Desulfovibrio or delay in growth of Desulfovibrio.

### Claim 17 (depends on 1)

The method of claim 1 further comprising administering a probiotic and/or a probiotic group.

### Claim 18 (depends on 17)

The method of claim 17, wherein the probiotic and/or a probiotic group is selected from the group consisting of bacteria that competes with Desulfovibrio for nutrients and bacteria that inhibits growth of Desulfovibrio.
